iQflow, Wearable Insulin Pump 'iQpatch'... "Large-Scale Clinical Trial for Type 2 Diabetes Patients Begins"

[Asia Economy Reporter Hyunseok Yoo] IoFlow, a wearable drug delivery solution specialist company, announced on the 14th that it has completed the first patient registration for a clinical trial of the wearable insulin pump 'IoPatch' targeting type 2 diabetes patients.

This clinical trial is being conducted on 136 type 2 diabetes patients at seven tertiary hospitals in the metropolitan area, three tertiary hospitals outside the metropolitan area, and national university hospitals. Despite the COVID-19 situation, the company stated that there are many clinical trial applicants, so patient recruitment is expected to proceed smoothly. This clinical trial is the largest ever conducted in Korea using an insulin pump for type 2 diabetes patients.

IoPatch is a wearable insulin pump commercialized by IoFlow, the second in the world and the first in Korea. It is a product used by patients with type 1 and type 2 diabetes who require insulin. IoPatch is a wearable device attached to the body without an infusion line, allowing insulin injection and blood glucose monitoring via smartphone by attaching it once every 3.5 days instead of multiple daily insulin injections. It not only improves patients' quality of life but also minimizes exposure to medical history.

This clinical trial is a multi-center post-marketing clinical trial verifying the clinical efficacy of IoPatch by expanding its application to type 2 diabetes patients. The trial will be conducted using Narsha, a smartphone app for controlling the wearable insulin pump recently launched in Korea. It is being conducted with the future expansion of use among type 2 diabetes patients in mind, and the company plans to accelerate patient registration going forward.

Jaejin Kim, CEO of IoFlow, said, "We expect to secure meaningful data by mid-next year through this clinical trial," adding, "Based on clinical data, we will verify the safety and efficacy of IoPatch to promote effective and safe blood glucose control and strive to improve the quality of life for type 2 diabetes patients." He continued, "Although it is a difficult time due to COVID-19, we will do our best to ensure the clinical trial proceeds successfully through continuous communication with clinical hospitals."

This content was produced with the assistance of AI translation services.